VCG
UTHR icon

Vantage Consulting Group’s United Therapeutics UTHR Stock Holding History

Vantage Consulting Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-139
Closed -$21K – 1515
2020
Q4 		$21K Buy
+139
New +$18.2K ﹤0.01% 854

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vantage Consulting Group's UTHR Position: Q1 2021 in Review

Vantage Consulting Group sold out of United Therapeutics (UTHR) in Q1 2021, closing a stake of 139 shares — an estimated $21K sold.

Vantage Consulting Group first reported a position in UTHR in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 391 funds tracked by Wall St. Rank hold UTHR as of Q1 2021.

  • Vantage Consulting Group reported no remaining United Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 139 United Therapeutics shares in Q1 2021, an estimated $21K.
  • Vantage Consulting Group first reported a position in United Therapeutics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's United Therapeutics position peaked at $21K in Q4 2020.
  • 391 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.